Oscar Arrieta, Head of the Thoracic Oncology Unit and Personalized Medicine Lab at INCan, shared on X:
“Neoadjuvant or perioperative treatment? A review that analyzes the most recent evidence on immunotherapy and biomarkers in non-small cell lung cancer, with the participation of Jose F. Corona-Cruz and colleagues.”
Title: Navigating Multimodality Therapy in Non–Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches
Authors: Gökce Yavuz, Michael Wang, Jonathan D. Spicer, Tina Cascone, and José Francisco Corona-Cruz
